Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIBIL: FOLFIRI vs 5-FU/folinic acid as second-line therapy in biliary tract cancer
DRKS00012595Phase 2Completed
- Sponsor
- Universitätsklinikum Frankfurt
- Start
- Jun 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, fluorouracil and folinic acid in biliary cancer, intrahepatic cholangiocarcinoma (ICC) and gallbladder cancer (2 arms), sponsored by Universitätsklinikum Frankfurt. Started Jun 2017; status: completed.
02
Drugs
irinotecanfluorouracilfolinic acid
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)gallbladder cancer
Beyond the preview
Go deeper on DRKS00012595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00012595.